Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 39, Issue 3, Pages 193-200Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2011.09.029
Keywords
CA-MRSA; Prevention; Control; Clinical studies
Funding
- International Society of Chemotherapy through Astellas
- International Society of Chemotherapy through Becton Dickinson
- International Society of Chemotherapy through Cepheid
- International Society of Chemotherapy through Novartis
- International Society of Chemotherapy through Pfizer
- Health Department of Western Australia
- Australian Federal Government
- NIH/NIAMS
- NIH/NIAID
- NIH/NHGRI
- Pfizer
- Cubist
Ask authors/readers for more resources
The rapid dissemination of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA) since the early 2000s and the appearance of new successful lineages is a matter of concern. The burden of these infections varies widely between different groups of individuals and in different regions of the world. Estimating the total burden of disease is therefore problematic. Skin and soft-tissue infections, often in otherwise healthy young individuals, are the most common clinical manifestation of these infections. The antibiotic susceptibilities of these strains also vary, although they are often more susceptible to 'traditional' antibiotics than related hospital-acquired strains. Preventing the dissemination of these organisms throughout the general population requires a multifaceted approach, including screening and decolonisation, general hygiene and cleaning measures, antibiotic stewardship programmes and, in the future, vaccination. The current evidence on the prevention and control of CA-MRSA is appraised and summarised in this review. (C) 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available